“When we used immunotherapies on these mice they were not able to respond as effectively as those which had not been stressed,” Dr Mattarollo said.
“This is because the stress led to poor function against the cancer by T-cells, which are very important in the immune system’s control and surveillance of tumours and are a major target in many immunotherapy treatments.”
Dr Mattarollo said increased anxiety was natural with a cancer diagnosis, and it should be managed to ensure the best possible outcome for patients.
“Absolutely there is now pre-clinical evidence to suggest that treatments and lifestyle interventions to manage or reduce stress levels will improve the chances of these patients responding to therapies,” he said.
“This applies particularly to immunotherapies, but many conventional therapies such as chemotherapy also rely on components of the immune system for their effectiveness.
“It is quite possible that by increasing the immune function in patients they will also respond better to some other therapies.”
PhD candidate Michael Nissen said as immunotherapies became more widely available, it was important to build on the knowledge of factors which influence their effectiveness.
“The more we know, the better chance we have of designing them effectively and efficiently to work in cancer patients,” Mr Nissen said.
Dr Mattarollo said the lab was hoping to combine immunotherapy treatments with commonly used blood pressure drugs that block the effects of stress hormones.
“We hope this will reduce the stress-induced neural signalling and improve immune function,” Dr Mattarollo said.
“We are about to test this combination in animal models.”
Dr Mattarollo said psychoneuroimmunology – or the interaction between the mind, the nervous system and the immune system – is a rapidly growing discipline and is becoming an increasing focus of the lab’s cancer research.
Source : The University of Queensland